ibrutinib,rituximab
abbvie,janssen
[' ibru', 'lymsm']
incredible study in mcl with clean and crisp design that challenges whether we need autosct if replaced with fixed-duration ibrutinib maintenance - also a beautiful example of the impact an iit can have! #lymsm #ash22 (and fantastic continued summaries from !) 
Heme/Onc fellow @UChicagoMed, alumna of @MedChiefs @UCSFMedicine @Harvard. Views are my own.